Alopexx Collaborates with Bharat Biotech to Develop Broad-Spectrum Antimicrobial Vaccine AV0328
Thursday, September 12, 2024
Alopexx has announced a partnership with Bharat Biotech to co-develop and commercialize its broad-spectrum antimicrobial vaccine, AV0328, in India and other low- and lower-middle-income countries.
Through this collaboration, the two companies will work together to advance and market AV0328, a synthetic vaccine that targets poly N-acetyl glucosamine (PNAG), across India and other designated regions. As part of the agreement, Alopexx will receive a one-time upfront payment, milestone payments, and royalties on future AV0328 sales in these licensed areas.
By joining forces with Alopexx, Bharat Biotech aims to bring AV0328 to the region’s most in need, aligning with the mission to develop vaccines that reduce antimicrobial resistance and provide safe, affordable, and high-quality solutions to combat infectious diseases worldwide.
AV0328 is a synthetic vaccine designed to target PNAG, a substance present on the surface of various bacterial, fungal, and parasitic pathogens. Preclinical studies have shown that targeting PNAG is effective in preventing and treating infections caused by more than 15 different pathogens.
A completed Phase I, first-in-human trial demonstrated that AV0328 is well-tolerated with no serious adverse events and successfully induced antibodies capable of eliminating a wide range of PNAG-expressing pathogens, highlighting its potential as a broad-spectrum antimicrobial vaccine.
This partnership marks a significant step towards addressing the urgent need for affordable, broad-spectrum antimicrobial solutions, particularly in low- and middle-income nations.
Source: globenewswire.com
